Intellia Therapeutics Announces Pricing of Initial Public Offering
06 May 2016 - 9:02AM
Intellia Therapeutics, Inc. (”Intellia Therapeutics” or “Intellia”)
a leading gene editing company focused on the development of
potentially curative therapeutics using CRISPR/Cas9 technology,
today announced the pricing of its initial public offering of
6,000,000 shares of common stock at a public offering price of $18
per share. In addition, Intellia has granted the underwriters a
30-day option to purchase up to 900,000 additional shares of common
stock at the initial public offering price, less the underwriting
discount. Intellia’s common stock is expected to begin trading on
the NASDAQ Global Market under the ticker symbol "NTLA" on May 6,
2016.
Credit Suisse, Jefferies LLC, and Leerink Partners are acting as
joint book-running managers for the offering. Wedbush PacGrow is
acting as lead manager.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on May
5, 2016. The offering will be made only by means of a prospectus.
Copies of the final prospectus related to the offering may be
obtained, when available, from: Credit Suisse Securities (USA) LLC,
Attn: Prospectus Dept., One Madison Avenue, New York, NY 10010, by
telephone at (800) 221-1037 or by email at
newyork.prospectus@credit-suisse.com; Jefferies LLC, Attn: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, by telephone at 877-547-6340 or by email at
Prospectus_Department@Jeffries.com; or Leerink Partners LLC, Attn:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at 800-808-7525 ext. 6142 or by email
at Syndicate@Leerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics is a leading gene editing company focused
on the development of proprietary and potentially curative
therapeutics using CRISPR/Cas9 technology.
Contacts:
Jennifer Mound Smoter
Chief External Affairs & Communications Officer
224-804-4462
jenn.smoter@intelliatx.com
John Graziano
Trout Group
646- 378-2942
Chad Rubin
Trout Group
646 378-2947
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024